Iovance Biotherapeutics, Inc. (IOVA)
Nasdaq: IOVA · Biological Products, (No Diagnostic Substances) · San Carlos, CA · filing with the SEC since 2008
Filings
388 filings since 2017 beside 252 insider forms · Accelerated filer · read from EDGAR on Nov 13, 2026Due nextAccelerated filer
10-K
Annual report for the fiscal year ending Dec 31, 2026Accelerated filers have 75 days after the fiscal year ends.
by Mar 16, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by May 10, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 36 days after the quarter ended. The proxy statement was last filed Apr 28, 2026.
Filings a yearinsider forms included
4549475980916672
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 6 times in the last 36 months, the newest Mar 20, 2026.SEC letters: 2 in the last 36 months, the newest Nov 21, 2023.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Aug 7, 2025
8-K items 2.02, 5.02, 9.01
Results released; Officer or director change · Current report
40 of 388 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.